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Abstract
Background: The optimal treatment regimen or protocol for managing a persistent patent ductus arteriosus (PDA)
in extremely low birth weight (ELBW) infants has not been well established. This study was aimed at evaluating the
failure rate of a cyclooxygenase (COX) inhibitor (COI) for PDA closure and to determine the incidence of a PDA
requiring ligation in ELBW infants. We examined the clinical characteristics and risk factors that may predict the
clinical consequences of failure of PDA closure by COI.
Methods: Medical information on 138 infants with birth weight (BW) < 1000 gm who survived for > 48 hours was
retrieved. Clinical characteristics and outcomes of patients whose PDAs closed with COI were compared with those
who did not close.
Results: Of the 138 patients, 112 survived to discharge. Eighty (71.4%) of those who survived received 1-3 courses
of COI treatment for a symptomatic PDA. A total of 32 (40%) failed COI treatment and underwent PDA ligation.
Multivariable logistic regression analysis suggests that the observed differences in the outcomes in infants with or
without symptomatic PDA can be explained by the babies with symptomatic PDA being more immature and
sicker. No significant difference was seen in the incidence of chronic lung disease (CLD) in infants whose PDA was
treated medically versus those who failed medical treatment and then underwent ligation. However, after adjusting
for disease severity and other known risk factors, the odds ratio of developing CLD for surviving babies with a
persistent PDA compared to those whose PDA was successfully closed with 1-2 courses of COI is 3.24 (1.07-9.81; p
= 0.038).
Conclusions: When successfully treated, PDA in ELBW infants did not contribute significantly to the adverse
outcomes such as CLD, retinopathy of prematurity (ROP) and age at discharge. This suggests that it is beneficial for
a hemodynamically significant PDA to be closed. The failure of a repeat course of COI to close a PDA is a major
risk factor for developing CLD in ELBW infants.
Background
Spontaneous closure of the ductus arteriosus (DA)
usually occurs within hours to days after birth in term
infants. However, the incidence of failure of DA closure
in premature infants ranges from 10% to 60% depending
on the gestational age, birth weight and diagnostic cri-
teria used [1,2]. In extremely low birth weight (ELBW)
infants (birth weight less than 1000 grams), only 34%
have a spontaneous permanent closure of the DA [3]. A
significant left-to-right shunt through the PDA may
increase morbidity and therefore contribute to mortality
in premature infants. The increased pulmonary blood
flow due to a left to right shunt through a PDA can
lead to deterioration of the respiratory status of prema-
ture infants and may contribute to the development of
bronchopulmonary dysplasia (BPD) or chronic lung dis-
ease (CLD) [4]. A patent ductus arteriosus (PDA) with a
significant left-to-right shunt may also increase the risk
for renal insufficiency, reduced brain perfusion [5] and
possible necrotizing enterocolitis (NEC) [6].
Although indomethacin, a cyclooxygenase inhibitor
(COI), is very effective in closing the DA of preterm
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infants [7,8], its efficacy is limited in very immature
infants [9]. In ELBW infants, the success rate of DA clo-
sure after the first course of indomethacin has been
reported to be between 20 and 40% [9,10]. When a PDA
fails to close after medical management or when treat-
ment with COI is contraindicated, surgical ligation is an
alternative. Currently, most neonatologists use repeat
courses of indomethacin or ibuprofen in an attempt to
close the PDA before committing the patient to surgical
ligation [6,11]. Recent studies have suggested an
increased risk of CLD, ROP and/or neurosensory
impairment may be associated with PDA ligation
[12,13]. However, it is unclear whether the clinical con-
dition of the baby requiring surgical ligation or the pro-
cedure itself contributes to an adverse outcome [2].
Therefore, the optimal treatment regimen for a persis-
tent PDA in ELBW infants has not been established.
The aim of the current study was to evaluate the clinical
course of ELBW infants with a PDA treated with COI,
the rate of failure of COI for PDA closure and the inci-
dence of PDA requiring surgical ligation. We compared
the clinical characteristics and outcomes of babies
whose PDA were successfully closed by COI with those
whose DA remained patent after COI treatment and
determined if any of these factors contributed to the
clinical outcomes of the ELBW infants.
Methods
We performed a retrospective data analysis. Medical
information of infants with a birth weight (BW) < 1000
gm born at the Mount Sinai Medical Center in New
York between August 1, 2004 and July 31, 2009 was
retrieved from our perinatal data base and medical
records. The study was approved by the Program for the
Protection of Human Subjects of the Mount Sinai Medi-
cal Center. It was our practice during that period to: 1)
perform echocardiography only when a PDA was sus-
pected due to the presence of a murmur, wide pulse
pressure, or deterioration of pulmonary status possibly
secondary to left to right shunting; 2) treat a PDA with
COI in infants who were diagnosed with a hemodynami-
cally significant PDA as judged by our attending neona-
tologists and/or confirmed by echocardiography; 3) use
indomethacin as the preferred choice, but use ibuprofen
for some babies with decreased urine output; 4) not use
indomethacin for prophylactic ductal closure in infants
less than 48 hours of age; 5) give indomethacin 0.2 mg/
kg every 12 hours for 3 doses or ibuprofen 10 mg/kg
followed by 5 mg/kg daily for 2 more doses as one
course; 6) obtain echocardiagraphy confirmation of a
moderate to large PDA with significant left to right
shunt before surgical ligation; 7) give a third course of
COI when PDA ligation could not be done expeditiously
due to scheduling issues. We collected clinical data and
determined the incidence of spontaneous closure of the
DA, the failure rate of 1-3 courses of COI for PDA, the
incidence of PDA treated with surgical ligation, and the
clinical outcomes of these infants. Successful PDA clo-
sure was defined as disappearance of the PDA murmur
and/or echocardiogram evidence of PDA closure. Echo-
cardiographic evidence of trivial flow through DA and
no further treatment needed was considered to have
closed PDA.
The clinical data collected included gestational age,
birth weight, gender, Apgar scores, admission tempera-
ture, first arterial blood gas, surfactant treatment, dura-
tion of intubation for mechanical ventilation, total fluid
administered during the first three days of life, and the
age when an infant received the first course of COI. The
urine output, serum sodium concentration, body weight
and total fluid status before, during and after the first
course of COI were also recorded. The disease severity
was quantified by the oxygenation index (OI) and the
five-item clinical risk index for babies (CRIB) II score as
described [14,15]. The clinical outcome measurements
include the age at extubation, the age at full enteral
feeds (defined as baby receiving no intravenous fluid
and > 120 ml/k.day of enteral feeds), the incidence of
severe (grade 3 or grade 4) intraventricular hemorrhage
(IVH), CLD (defined as supplemental oxygen require-
ment at 36 weeks postmenstrual age), ROP, necrotizing
enterocolitis (NEC) with Bell stage II or higher, blood
culture proven bacteremia, and the age at discharge.
Data analysis was conducted with PASW Statistics
18.0 (SPSS Inc.). Continuous variables between groups
were compared using the T-test for independent sam-
ples for normally distributed data and the Mann-Whit-
ney test for non-normally distributed data. Proportions
between groups were compared using the Chi-square
test. For dichotomous outcomes, odds ratios adjusted
for confounding and effect modifiers were determined
using logistic regression as indicated in the text. For
continuous outcome varibles, multivariable regression
analysis was used to determine the effect of a PDA and
its treatment as indicated in the text. The data are pre-
sented as mean (standard error of the mean) and P <
0.05 is considered significant.
Results
A total of 189 infants with a BW < 1000 gm were born
at the Mount Sinai Hospital between August 1, 2004
and July 31, 2009. Of those patients, 14 patients with
major congenital anomalies and 37 who died at age <
48 hours of life were excluded from the analysis.
Data from the remaining 138 patients were reviewed.
Among those 138 patients, 26 died before discharge.
Seven of those 26 died at age ≤ 7 days of life. The
causes of death for those 26 patients were mainly
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respiratory failure due to extremely immature lungs (13/
26). Other causes of death include NEC or sepsis (9/26),
severe IVH (2/26), and twin to twin transfusion (2/26).
Of the 112 babies who survived to discharge, 32 (28.6%)
did not develop a hemodynamically significant PDA (the
DA closed spontaneously). The remaining 80 patients
(71.4%) were diagnosed with a hemodynamically signifi-
cant PDA and received at least one course of COI.
Among the 80 patients who received COI treatment for
a PDA, 26 (32.5%) infants closed their PDA after one
course of COI. One infant had her PDA ligated after the
failure of one course of COI to achieve ductal closure
due to significant side effects of COI usage. The remain-
ing 53 patients received a second course of COI and 16
of these patients (30.2%) closed their PDA after the sec-
ond course of COI. Therefore, there were a total of 37
of 80 patients (46.2%) whose DA remained clinically sig-
nificant after 2 courses of COI treatment. PDAs were
ligated in 22 out of these 37 patients after the second
course and the other 15 babies received a third course
of COI. Among the 15 infants who received a third
course, 6 (40%) closed their PDA and the remaining 9
infants underwent PDA ligation. Therefore, a total of
32/80 (40%) underwent surgical ligation of the PDA.
Most of the ligations were performed in the second or
third week of life.
Detailed analysis was done on those 112 patients who
survived to discharge. The demographics of infants with
vs. those without hemodynamically significant PDAs are
shown in Table 1. The babies with hemodynamically
significant PDAs were less mature, had lower birth
weights, higher CRIB II scores, higher OI, and received
more fluid during the first 3 days of life. The overall
outcomes for babies with hemodynamically significant
PDAs were worse, as evidenced by an older age at extu-
bation, reaching full enteral feeds later, and having a
longer duration of hospitalization. Furthermore, the
babies with hemodynamically significant PDAs had a
higher incidence of CLD and ROP.
In order to ascertain whether these adverse outcomes
in the babies with hemodynamically significant PDA
might be attributable to the pre-existing risk factors of
lower birth weight, lower gestational age, higher CRIB II
scores, and higher OIs in these infants, we performed a
multivariable logistic regression analysis. Since both
birth weight and gestational age are included in the
CRIB II score, logistic regression with CLD as the clini-
cal outcome adjusted for CRIB II and OI was per-
formed. This analysis reveals an adjusted odds ratio for
CLD in those with vs. those without PDA of 1.10 (95%
confidence interval [CI]: 0.37 - 3.30, P = 0.867). Simi-
larly, the adjusted odds ratio for ROP in those with vs.
those without symptomatic PDA is 3.20 (95% CI: 0.93 -
11.10, P = 0.065). These data suggest that the observed
difference in CLD and ROP in babies with hemodynami-
cally significant PDA vs. those without can be explained
by the babies with hemodynamically significant PDA
being less mature, having a lower birth weight, and
being sicker as indicated by higher CRIB II scores and
OI. Furthermore, multivariable regression analysis shows
that a hemodynamically significant PDA did not add sig-
nificantly to either CRIB II score or gestational age
alone as a predictor of age at extubation or age at dis-
charge. However, a multivariable regression analysis
shows that the addition of a hemodynamically signifi-
cant PDA to either CRIB II (R2 increases from 0.176 to
0.234 by addition of PDA to the model, p = 0.006) or
gestational age (R2 increases from 0.195 to 0.232 by
addition of PDA to the model, p = 0.025) improves a
regression model for predicting age at full feeds. Pre-
sence of a hemodynamically significant PDA prolongs
the time to full feeds by 8.0 ± 2.8 days in the multivari-
able model with CRIB II score and by 6.8 ± 3.0 days in
the model with gestational age.
Among the 80 patients who received COI treatment
for PDA, 26 (32.5%) infants closed their PDA after one
course of COI. The comparisons of the infants whose
DA closed with 1st course vs. who did not close with 1st
course are presented in Table 2. As shown in the Table
2, other than the babies whose PDA was closed with the
first course of COI being slightly more mature than
those whose PDA did not close, none of the factors that
we examined distinguished infants who responded to
one course COI vs. those who did not.
The baseline characteristics of infants whose PDA
closed with either one course or two courses of COI vs.
those whose DA remained patent after 2nd course of
COI are presented in Table 3. The babies whose PDA
Table 1 Demographics of the ELBW infants who survived
to discharge
No PDA (n = 32) PDA (n = 80) P
BW, gm 815 (20) 753 (14) 0.015
GA, wks 27.3 (0.4) 25.2 (0.1) < 0.001
Male Gender (%) 14 (44%) 38 (48%) ns
CRIB II score 9.9 (0.4) 12.4 (0.2) < 0.001
OI 3.1 (0.5) 4.2 (0.3) 0.033
Surfactant use 23 (71.9%) 77 (96.3%) 0.001
Intubated > 2 days 18 (56.3%) 71 (88.8%) < 0.001
Fluid 1st 3 days, ml/k/d 102 (3) 113 (2) 0.045
CLD 10 (31.3%) 42 (52.5%) 0.042
NEC 3 (9.4%) 8 (10.0%) ns
IVH III-IV 0 (0.0%) 6 (7.5%) ns
ROP 6 (18.8%) 51 (63.8%) < 0.001
Age at extubation, days 8 (3) 29 (4) < 0.001
Age at full feeds, days 21 (1) 33 (2) < 0.001
Age at discharge, days 83 (5) 105 (6) 0.041
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closed with either one or two courses of COI were
slightly more mature than those who had persistent
hemodynamically significant PDA but were otherwise
not different (we excluded the baby whose PDA was
ligated after the first course of COI). As is shown in
Table 4, the incidence of CLD in infants whose DA
remained patent after two courses of COI was almost
twice that of babies whose DA closed with either one or
two courses of COI. Furthermore, logistic regression
analysis shows that, when compared to those whose
PDA was successfully closed with the first or second
course of COI, after adjusting for CRIB II score, OI,
intubation for more than 2 days, and culture proven
later onset bacteremia, the odds ratio of having CLD for
surviving babies with persistent hemodynamically signif-
icant PDA is 3.24 (95% CI: 1.07 - 9.81, p = 0.038). Add-
ing PDA ligation as a potential confounder did not
improve the logistic model. These data demonstrate that
failure of closure of PDA after 2 courses of COI is a sig-
nificant risk factor for development of CLD in ELBW
infants.
Table 5 shows a comparison of infants with PDA
which closed with one (n = 26), two (n = 16), or three
(n = 6) courses of COI vs. those who underwent surgical
ligation after failure of one (n = 1), two (n = 22), or
three (n = 9) courses of COI. Other than the fact that
babies whose DAs were ligated received more courses of
COI, neither the risk factors nor the outcomes we
examined distinguished the babies who underwent liga-
tion from those who did not.
Discussion
In this retrospective data analysis study, we found that
less than one third of the ELBW infants who survived
to discharge closed their DA spontaneously. The babies
who had spontaneous closure of their DA were more
mature, had a higher birth weight, and were less ill as
indicated by lower CRIB II scores and lower OI. As
compared to those who had a symptomatic PDA requir-
ing treatment, the overall outcomes for the babies who
closed their DA spontaneously were better, as demon-
strated by a younger age at extubation, reaching full ent-
eral feeds earlier, and having a shorter duration of
Table 2 Comparisons of the ELBW infants whose DA
closed with 1st course of COI vs. who did not close with
1st course
Closed (n = 26) Not Closed (n = 54) P
BW, gm 764 (23) 749 (17) ns
GA, wks 25.6 (0.2) 25.0 (0.1) 0.014
Male Gender (%) 14 (54%) 24 (44%) ns
CRIB II score 12.0 (0.4) 12.6 (0.3) ns
OI 3.4 (0.3) 4.5 (0.3) ns
Age 1st Dose, days 5.5 (0.8) 6.8 (1.4) ns
Fluid 1st 3 days, ml/k/d 114 (5) 113 (2) ns
UOP before Rx, ml/k/h 3.7 (0.2) 3.9 (0.2) ns
UOP during Rx, ml/k/h 3.3 (0.3) 3.2 (0.2) ns
UOP after Rx, ml/k/h 3.3 (0.3) 3.2 (0.2) ns
Table 3 Baseline characteristic of the ELBW infants whose
DA was closed after 2nd course COI vs. those whose DA
remained patent after 2nd course
Closed (n = 42) Not Closed (n = 37) P
BW, gm 777 (17) 724 (21) ns
GA, wks 25.5 (0.2) 24.9 (0.2) 0.007
Male Gender (%) 23 (55%) 15 (41%) ns
CRIB II score 12.0 (0.3) 12.9 (0.4) ns
OI 3.7 (0.3) 4.7 (0.5) ns
Intubated > 2 days 36 (85.7%) 34 (91.9%) ns
Age 1st Dose, days 5.6 (0.6) 7.3 (2.0) ns
Table 4 Outcomes of the ELBW infants whose DA was
closed after 2nd course COI vs. those whose DA
remained patent after 2nd course
Closed (n = 42) Not Closed (n = 37) P
CLD 16 (38.1%) 25 (67.6%) 0.013
NEC 5 (11.9%) 3 (8.1%) ns
IVH III-IV 3 (7.1%) 3 (8.1%) ns
ROP 27 (64.3%) 24 (64.9%) ns
Age at extubation, days 27 (6) 33 (5) ns
Age at full feeds, days 33 (2) 34 (2) ns
Age at discharge, days 101 (4) 109 (13) ns
Table 5 Comparisons of ELBW infants with PDA closed by
COI treatment vs. those with PDA who failed medical
treatment and underwent surgical ligation
COI Only (n =
48)
COI & Ligation (n =
32)
P
BW, gm 772 (16) 726 (24) ns
GA, wks 25.4 (0.2) 24.9 (0.2) ns
Male Gender (%) 26 (54%) 12 (38%) ns
CRIB II score 12.1 (0.3) 12.9 (0.4) ns
OI 3.9 (0.3) 4.5 (0.5) ns
COI courses 1.6 (0.1) 2.3 (0.1) <
0.001
Age 1st Dose, days 5.6 (0.6) 7.5 (2.3) ns
CLD 21 (43.8%) 21 (65.6%) ns
NEC 6 (12.5%) 2 (6.3%) ns
IVH III-IV 4 (8.3%) 2 (6.3%) ns
ROP 29 (60.4%) 22 (68.8%) ns
Age at extubation,
days
27 (5) 33 (5) ns
Age at full feeds,
days
33 (2) 34 (2) ns
Age at discharge,
days
102 (4) 110 (14) ns
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hospitalization, and with lower incidences of CLD and
ROP. These data are well known and consistent with
numerous reports in the literature [3,16-18]. However,
our analysis using multivariable logistic regression sug-
gests that the observed difference in outcomes such as
CLD and ROP in ELBW infants with a symptomatic
PDA vs. those without can be explained by the babies
with a symptomatic PDA being less mature and sicker
(by CRIB II and OI). Furthermore, regression analysis
shows that a hemodynamically significant PDA as mana-
ged in our NICU does not add significantly to either
CRIB II score or gestational age alone as predictors of
age at extubation or age at discharge.
Recent papers have suggested that there is little evi-
dence of benefit of closing a PDA in extremely preterm
infant and that potential side effects and complications
related to COI and surgery are significant [6,19]. How-
ever, in a recent study from Western Australia, where
surgical ligation was not practical, persistent PDA when
left untreated was associated with much higher mortal-
ity, even after adjustment was made for initial disease
severity, gestational age and other perinatal factors [20].
In addition to their being a well accepted association
between CLD and PDA, our data also suggest that it is
beneficial for a hemodynamically significant PDA in
ELBW infants to be closed. This evidence supports the
current practice of closing all hemodynamically signifi-
cant PDAs in ELBW infants.
The presence of a hemodynamically significant PDA
prolongs the time to full feedings by approximately one
week in the multivariable model with either CRIB II
score or gestational age. This is not surprising since it
was our practice to routinely withhold feedings in babies
whom we treated for PDA. The practice of withholding
feedings or not initiating enteral feeds in babies who are
receiving COI was based mainly on the concern that use
of indomethacin may increase the risk for spontaneous
intestinal perforation [21]. Indeed, by using multivariate
regression analysis and two different derivations with a
national dataset, Attridge et al. found significant associa-
tions between early use of indomethacin and sponta-
neous intestinal perforation [22]. However, they did not
find an association with indomethacin when it was given
after day of life four [22]. Therefore, withholding enteral
feedings may not be necessary in extremely premature
infants who are receiving COI treatment for PDA after
day of life four.
In our NICU, COI treatment was initiated relatively
late as compared to other published studies, and this
may explain our relatively higher failure rate of COI
treatment for PDA. We do not routinely perform
screening echocardiograms in all ELBW infants in our
NICU. It has been shown that a conservative approach
for PDA management was associated with decreased
rates of surgical ligation without significantly increased
morbidity in extremely premature infants [23]. In the
current study, surgical ligation was reserved for PDA
closure when treatment with COI failed or was contra-
indicated. No indomethacin was given within 48 hours
of age as prophylaxis and most surgical ligation hap-
pened between 2-3 weeks of life. Complications of surgi-
cal ligation were not observed in our series. Recently, a
few studies have reported that surgical ligation is a risk
factor associated with CLD [13,24]. Whether this asso-
ciation is related to surgical ligation, the PDA itself, or
just extreme prematurity has been a matter of debate
among neonatologists. Although in our study no statisti-
cally significant difference was seen in the incidence of
CLD in infants whose PDA responded to COI treatment
versus those who failed and then underwent surgical
ligation, our numbers are quite small. Interestingly, the
incidence of CLD in infants whose DA remained patent
after 2 courses of COI was almost twice that of babies
whose DA closed with either the first or second course
of COI. After adjusting for CRIB II score, OI, intubation
for more than 2 days, and culture proven bacteremia,
the odds ratio of having CLD in surviving babies with
persistently hemodynamically significant PDA is still sig-
nificantly higher when compared to those whose PDA
was successfully closed with one or two courses of COI.
This may suggest that the failure of closure of a PDA
with a second course of COI rather than surgical liga-
tion is a significant risk factor for developing CLD in
ELBW infants.
Adding PDA ligation as a factor did not improve the
logistic model for an adjusted odd ratio of having CLD
in ELBW infants who did not respond to a 2nd course
of COI. This may suggest that some intrinsic factors
which cause the DA to fail to respond COI treatment
may contribute to the pathogenesis of CLD. However,
our study is limited due to its retrospective nature.
Furthermore, due to the small number of patients in
our study and the arbitrary nature of the decisions to
pursue surgical ligation vs. a third course of COI after
failure of a 2nd course of COI, we cannot comment on
the potential role of the third course of COI for closure
of PDA and the role of surgical ligation in the develop-
ment of CLD. Nevertheless, it may be beneficial to
indentify potential clinical factors that predict the failure
of COI treatment for PDA to guide the clinical manage-
ment of PDA in ELBW infants. Unfortunately, we, as
well as others [25,26], are unable to identify any clinical
factors which can be reliably used to predict which spe-
cific infant will fail to close a hemodynamically signifi-
cant PDA with COI treatment. More recently, it was
demonstrated that using echocardiagraphy to direct the
use of COI may lead to fewer doses of COI for PDA
closure in premature infants [27]. This approach
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requires the availability of frequent echocardiographic
evaluation, which may be problematic in many neonatal
intensive care units.
Conclusions
In conclusion, 71.4% of ELBW infants who survived to
discharge were diagnosed with hemodynamically signifi-
cant PDA and received treatment. When treated, PDA
in ELBW infants did not contribute significantly to
adverse outcomes such as CLD, ROP and age at dis-
charge, suggesting that it is beneficial for a hemodyna-
mically significant PDA to be closed. The incidence of
CLD in infants whose DA remained patent after a 2nd
course of COI was almost twice that of those whose DA
closed with either one or two courses of COI. The
adjusted odds of having CLD for surviving babies with
persistent hemodynamically significant PDA is greater
than three times that of babies whose PDA was success-
fully closed with either one or 2 courses of COI. Adding
PDA ligation as a factor did not improve the logistic
model for adjusted odd ratio of having CLD in those
infants. This may suggest that persistent patency of the
DA after two courses of COI rather than PDA ligation
is a significant risk factor for developing CLD in ELBW
infants. Due to small numbers of infants who responded
to a third course of COI and the lack of obvious benefit,
we can not draw any conclusions regarding to the use
of third course COI in ELBW infants with hemodynami-
cally significant PDA who failed the 2nd course of COI.
The identification of reliable factors or biomarkers to
guide the use of COI [28] or surgery may ultimately
improve the outcomes of ELBW infants with hemodyna-
mically significant PDA and should be the direction of
future studies.
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